Compare iShares China Large-Cap ETF (FXI) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Humana Inc — how do they compare? iShares China Large-Cap ETF trades at $35.21, while Humana Inc trades at $384.67 (market cap $44.77B). The key difference: Humana Inc pays a 0.95% dividend while iShares China Large-Cap ETF pays none, and Humana Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | HUM | |
|---|---|---|
52-Week High | $41.75 | $409.42 |
52-Week Low | $31.59 | $163.67 |
Market Cap | — | $44.77B |
Sector | — | Health |
Enterprise Value | — | $52.12B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $35.205, down 3.52% amid broader pressure on Chinese equities. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral. Recent news highlights China's export strength and AI-driven manufacturing rebound, while the ETF offers exposure to state-backed economic initiatives and upcoming dividend payments.
The outlook for FXI hinges on China's economic stabilization efforts and global demand for tech exports. Investment opportunities include diversification from US markets and exposure to AI hardware growth, but risks include US-China tensions, regulatory uncertainty, and value trap potential in Chinese equities.
Humana (HUM) trades at $386.11, up 0.17% today, with a neutral technical outlook and mixed fundamentals. The stock shows strong revenue growth reaching $129.66B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent Q2 2026 earnings beat expectations with EPS of $7.61 versus $7.27 expected, while management focuses on Medicare Advantage margin expansion and cost reductions.
Outlook remains cautiously optimistic with a consensus price target of $409.93 offering 6% upside potential. Key opportunities include Medicare Advantage growth and operational efficiency gains, while risks involve margin pressure, regulatory changes in healthcare, and competitive threats. Analyst sentiment leans neutral with 57% hold ratings amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
